Actively Recruiting
Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
Led by Hospital Universitario 12 de Octubre · Updated on 2025-05-14
109
Participants Needed
4
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are: I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?
CONDITIONS
Official Title
Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Presence of atrial fibrillation or atrial flutter not self-limited.
- Cardiac imaging test showing left ventricular ejection fraction below 50% during arrhythmia.
- Imaging test performed within 3 months before rhythm control procedure without intervening cardiovascular events.
- If previously known LVEF below 50%, there must be a decrease of at least 10% attributable to arrhythmia.
- Signed informed consent.
- Ability to understand and accept participation in the study.
You will not qualify if you...
- Refusal to provide informed consent.
- Legal or judicial incapacity.
- Age under 18 years.
- Life expectancy less than 1 year.
- Unable to have at least 6 months of follow-up.
- Ventricular rate over 140 beats per minute affecting imaging validity.
- Known causes of systolic ventricular dysfunction including prior cardiomyopathy diagnosis, severe mitral or aortic valve disease, non-revascularizable ischemic heart disease, peri-resuscitation cardiopulmonary care context.
- Excessive alcohol consumption defined as over 80 grams of ethanol or more than 7 standard alcoholic drinks per day.
- Active chemotherapy or chest radiation treatment.
- Known infection with Trypanosoma cruzi, Borrellia burgdorferi, or other infections causing cardiomyopathy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Ciudad Real General University Hospital
Ciudad Real, Castille-La Mancha, Spain, 15004
Actively Recruiting
2
12 de Octubre University Hospital
Madrid, Madrid, Spain, 28004
Actively Recruiting
3
Albacete University Hospital Complex
Albacete, Spain
Not Yet Recruiting
4
Ramón y Cajal University Hospital
Madrid, Spain
Active, Not Recruiting
Research Team
M
Martín Negreira-Caamaño, MD, PhD
CONTACT
D
Daniel Rodríguez-Muñoz, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here